Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› New Jersey
Clinical trial register · United States · industry-sponsored

Clinical Trials in New Jersey, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9148 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 21 Nov 2026, 03:16 UTC
9148
Studies in scope
industry-sponsored, all four open statuses
4975
Recruiting now
open to new participants
2181
Lead sponsors
across recruiting studies
Top states
California 5328 Florida 4488 Illinois 2493 Georgia 2364 Arizona 2269

Trials with a site in New Jersey

787 of 9148 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Neola Medical Inc
Not applicable
22
California, New Jersey
2027-06
Not yet open
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
NCT06708455Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc, Malignant Melanoma Stage IV
DrugRAPA
Rapa Therapeutics LLC
Phase 2
65
New Jersey
2027-03-01
Recruiting
Nuvation Bio Inc.
Phase 2
40
California, Connecticut, Florida, Indiana, Louisiana, Massachusetts, New Jersey, New York
2027-03
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
112
Connecticut, New Jersey, New York, Ohio, Texas, Washington
2026-12-31
Recruiting
A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs
NCT07905183Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive, Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML
Enliven Therapeutics
Phase 3
450
Georgia, Indiana, New Jersey, Utah
2026-12-31
Not yet open
Longbio Pharma (Suzhou) Co., Ltd.
Phase 2
80
Massachusetts, New Jersey, Pennsylvania
2026-12
Not yet open
Annovis Bio Inc.
Phase 2/3
400
Colorado, Florida, Georgia, New Jersey, North Carolina, Texas, Virginia
2026-11-21
Recruiting
Pfizer
Phase 3
900
California, Florida, New Jersey, Pennsylvania, Texas, Washington
2026-11-17
Not yet open
Merck Sharp & Dohme LLC
Phase 1
80
New Jersey
2026-11-13
Recruiting
Eli Lilly and Company
Phase 2
330
California, Florida, Georgia, Massachusetts, Nevada, New Jersey, New York, Pennsylvania
2026-11-10
Not yet open
GV101 for Friedreich's Ataxia (FA) Treatment
NCT07870590Friedreich's Ataxia
Graviton Bioscience Corporation
Phase 2
48
New Jersey
2026-11
Not yet open
Gilead Sciences
Phase 2
80
California, New Jersey
2026-11
Not yet open
Hummingbird ICE Study
NCT07552272ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION, Atrial Fibrillation (AF), Valve Disease, Heart, Atrial Septal Defect
Philips Clinical & Medical Affairs Global
Observational
1,000
Michigan, New Jersey
2026-11
Not yet open
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
NCT07873931Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
Bristol-Myers Squibb
Phase 1
60
California, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New York, Pennsylvania
2026-10-30
Not yet open
Eisai Inc.
Observational
270
New Jersey
2026-10-30
Recruiting
Takeda
Phase 2
36
California, Florida, Maryland, Missouri, New Jersey, New York, Ohio, Texas
2026-10-27
Recruiting
Eli Lilly and Company
Phase 1
617
Arkansas, California, Florida, Georgia, Missouri, New Jersey, Ohio, Texas
2026-10-22
Not yet open
Abbott Point of Care
Observational
425
New Jersey, Pennsylvania, Wisconsin
2026-10-22
Recruiting
Merck Sharp & Dohme LLC
Phase 2
480
New Jersey, Ohio, Oregon
2026-10-21
Recruiting
Biocomposites Ltd
Not applicable
139
California, Indiana, Maryland, New Jersey
2026-10-20
Recruiting
Viridian Therapeutics, Inc.
Phase 4
30
California, Florida, Massachusetts, Michigan, Missouri, New Jersey, Texas
2026-10-19
Recruiting
AiCuris Anti-infective Cures AG
Phase 2
24
Alabama, California, Florida, Georgia, Illinois, Maryland, Missouri, New Jersey
2026-10-05
Recruiting
Abiomed Inc.
Not applicable
250
California, Florida, Indiana, Minnesota, Missouri, New Jersey, New York, North Carolina
2026-10-02
Recruiting
Pluvicto Real-world Investigation in Survival in Metastatic CRPC
NCT07697989Prostatic Neoplasms, Castration-Resistant, Neoplasm Metastasis
Novartis Pharmaceuticals
Observational
1,085
New Jersey
2026-10-01
Recruiting
Boehringer Ingelheim
Phase 1/2
55
Florida, Massachusetts, New Jersey, New York, Tennessee
2026-10-01
Recruiting
First-in-human Study of UX016 in GNEM
NCT07511556GNE Myopathy
Ultragenyx Pharmaceutical Inc
Phase 1/2
24
California, New Jersey
2026-10
Not yet open
Gilead Sciences
Phase 1/2
100
California, New Jersey, New York, Utah
2026-10
Recruiting
Ray Therapeutics, Inc.
Phase 2/3
60
Arizona, California, Florida, Hawaii, Illinois, Michigan, Minnesota, New Jersey
2026-10
Not yet open
Eli Lilly and Company
Phase 2
50
Alabama, California, Florida, Massachusetts, New Jersey, Texas, Virginia, Wisconsin
2026-10
Recruiting
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
NCT07520006B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Nurix Therapeutics, Inc.
Phase 1/2
150
California, Colorado, Florida, Kansas, Nevada, New Jersey, Oregon, Pennsylvania
2026-09-30
Recruiting
RAI Services Company
Not applicable
480
Florida, Georgia, Illinois, New Jersey, Texas
2026-09-30
Not yet open
Hikma Pharmaceuticals USA Inc.
Phase 2
44
New Jersey, Utah
2026-09-28
Recruiting
Transcend Therapeutics
Phase 3
300
Colorado, Florida, Georgia, New Jersey, Utah
2026-09-25
Recruiting
HMPL-A830 in Solid Tumors
NCT07718581Solid Tumor, Adult
Hutchmed
Phase 1/2
147
California, Florida, New Jersey, Tennessee, Utah
2026-09-24
Recruiting
Jazz Pharmaceuticals
Phase 1
212
Nebraska, New Jersey
2026-09-22
Recruiting
Adneuris Therapeutics, Inc.
Phase 3
160
Arizona, California, Colorado, Georgia, Illinois, Maryland, New Jersey, Oklahoma
2026-09-22
Recruiting
NeuroOne Medical Technologies Corporation
Observational
100
Florida, New Jersey
2026-09-18
Recruiting
CSL Behring
Phase 3
63
California, Colorado, Florida, Indiana, Maryland, New Jersey, New York, North Carolina
2026-09-15
Recruiting
Merck Sharp & Dohme LLC
Phase 1
400
Florida, Maryland, Missouri, New Jersey, Ohio, Texas
2026-09-10
Not yet open
NinaMED Pty Ltd
Phase 3
290
New Jersey
2026-09-10
Recruiting
Pfizer
Phase 3
600
Arizona, California, Connecticut, District of Columbia, Idaho, Indiana, New Jersey, Ohio
2026-09-09
Recruiting
Hoffmann-La Roche
Phase 1/2
5
California, Connecticut, New Jersey, New York
2026-09-08
Recruiting
Regeneron Pharmaceuticals
Phase 1
36
Georgia, New Jersey, Oregon
2026-09-08
Recruiting
Kyowa Kirin, Inc.
Phase 1
72
California, Florida, Georgia, Iowa, Massachusetts, Missouri, New Jersey, New York
2026-09-02
Recruiting
Caliway Biopharmaceuticals Co., Ltd.
Phase 3
320
California, Florida, Illinois, Louisiana, Maryland, Nebraska, New Jersey, New York
2026-09-01
Recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
80
Florida, Louisiana, Massachusetts, Missouri, Nevada, New Jersey, New York, Ohio
2026-09-01
Not yet open
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
NCT07214974Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis
Noah Tech, Corp.
Early Phase 1
600
New Jersey
2026-09-01
Recruiting
Polyrizon Ltd.
Not applicable
120
Illinois, Missouri, New Jersey, Texas
2026-09-01
Not yet open
L'Oreal
Not applicable
130
New Jersey
2026-09-01
By invitation
Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study
NCT07197788Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes
Endogenex, Inc.
Not applicable
50
Florida, Massachusetts, New Jersey, North Carolina, Texas
2026-09
Not yet open
Reduction of Depression Through Dual Treatment: Digital CBT & NBHWC Coaching
NCT07195292Hearing Disability, Depression, Mobility Disability
Toivoa Inc
Not applicable
200
Delaware, New Jersey, Ohio, Texas
2026-09
Not yet open
Reduction of Anxiety Through Dual Treatment: Digital CBT & NBHWC Coaching
NCT07140497Hearing Disability, Anxiety, Mobility Disability
Toivoa Inc
Not applicable
200
Delaware, New Jersey, Ohio, Texas
2026-09
Recruiting
Harmony Biosciences Management, Inc.
Phase 1
12
New Jersey
2026-08-28
Recruiting
Genentech, Inc.
Phase 3
300
Alabama, California, Connecticut, District of Columbia, Michigan, Nevada, New Jersey, New Mexico
2026-08-25
Recruiting
AstraZeneca
Phase 3
500
California, Florida, Georgia, Illinois, Maryland, Missouri, Nevada, New Jersey
2026-08-24
Recruiting
Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel
NCT07765446Chemotherapy-induced Peripheral Neuropathy
Sironax USA, Inc.
Phase 2
18
Florida, Maryland, Massachusetts, New Jersey, North Carolina
2026-08-21
Recruiting
Pfizer
Phase 3
1,100
California, Florida, Maryland, Michigan, New Jersey, North Carolina, Oklahoma, Tennessee
2026-08-20
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
356
California, Florida, Illinois, Missouri, New Jersey, Ohio, Texas, Virginia
2026-08-19
Recruiting
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
NCT07745361Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma)
Monte Rosa Therapeutics, Inc
Phase 2
25
California, Colorado, Kansas, Maryland, Michigan, Nebraska, New Jersey, North Carolina
2026-08-18
Recruiting
Study to Assess KN3835 in the Treatment of Flexible/Semi-Flexible Hammertoe (HMT)
NCT07759362Flexible Hammertoe, Semi-flexible Hammertoe
DrugKN3835
Endo USA Inc., a Keenova Therapeutics Company
Phase 3
554
Arizona, California, Florida, Illinois, Kansas, New Jersey, Texas, Utah
2026-08-11
Recruiting
Nektar Therapeutics
Phase 3
510
Alabama, California, Florida, Georgia, Louisiana, Missouri, Nevada, New Jersey
2026-08-07
Recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
384
Arizona, California, Florida, Massachusetts, New Jersey, New York, Oklahoma, Oregon
2026-08-06
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
NCT07498335Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
28
New Jersey, Ohio, Oklahoma, Tennessee
2026-08-06
Recruiting
Larimar Therapeutics, Inc.
Phase 3
150
Florida, Illinois, New Jersey, Texas
2026-08-05
Recruiting
Sling Therapeutics, Inc.
Phase 3
130
Arizona, California, Florida, Massachusetts, Michigan, Nevada, New Jersey, New York
2026-08-04
Recruiting
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc
SystImmune Inc.
Phase 3
550
Arkansas, California, Florida, New Jersey, Virginia
2026-08-04
Recruiting
Leal Therapeutics, Inc
Phase 1
90
Arkansas, California, Florida, Georgia, Maryland, New Jersey, Texas
2026-08-03
Not yet open
Caring Technologies, Inc.
Not applicable
120
New Jersey
2026-08-01
Recruiting
Biogen
Phase 2
60
Arizona, California, Florida, Illinois, Maryland, New Jersey, North Carolina, Texas
2026-07-30
Recruiting
Gilead Sciences
Phase 2/3
700
California, Connecticut, Florida, Georgia, Missouri, New Jersey, Texas, Washington
2026-07-29
Recruiting
Sanofi
Phase 2
160
California, Florida, Massachusetts, New Jersey, Oregon, Pennsylvania, Rhode Island, Texas
2026-07-28
By invitation
Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study
NCT07676097Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
AngioInsight
Observational
620
California, District of Columbia, Minnesota, New Jersey, New York, Ohio, Tennessee
2026-07-28
Recruiting
Verastem, Inc.
Phase 2
150
Arizona, California, Florida, Indiana, Michigan, Missouri, New Jersey, New York
2026-07-28
Recruiting
AstraZeneca
Phase 1/2
101
California, Colorado, Florida, Georgia, Missouri, New Jersey, Ohio, Tennessee
2026-07-27
Recruiting
ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain
NCT07568015Greater Trochanteric Pain Syndrome, Greater Trochanteric Pain Syndrome of Both Lower Limbs, Lateral Hip Pain
Brixton Biosciences, Inc.
Not applicable
100
Arizona, Georgia, Louisiana, Massachusetts, New Jersey, Oklahoma, Pennsylvania, Texas
2026-07-27
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
AstraZeneca
Phase 3
230
Colorado, Maryland, Michigan, New Jersey, New York, North Carolina, Ohio, Utah
2026-07-24
By invitation
Case-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils
NCT07639853Arteriovenous Malformation, Gastrointestinal Bleed, Gastric Varices, Hemorrhoid
Medtronic Endovascular
Observational
30
New Jersey, New York, Texas
2026-07-24
By invitation
OsseoFit Stemless Shoulder System (Anatomic)
NCT07421245Shoulder Injuries, Shoulder Pain, Shoulder Fractures, Shoulder Arthritis
Zimmer Biomet
Observational
136
New Jersey, New York
2026-07-23
Recruiting
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07383506PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer
Cogent Biosciences, Inc.
Phase 1
90
Arizona, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Tennessee
2026-07-23
Recruiting
Gilead Sciences
Phase 1
112
California, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Nevada, New Jersey
2026-07-22
Recruiting
CathVision ApS
Observational
40
Michigan, New Jersey
2026-07-22
Recruiting
Verastem, Inc.
Phase 2
105
Arizona, California, Colorado, Florida, Georgia, Illinois, New Jersey, New York
2026-07-22
Recruiting
DBC-664 in Adult Patients With Solid Tumors
NCT07705035Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
Duboce Biopharmaceuticals, Inc.
Phase 1
210
Colorado, Michigan, Missouri, New Jersey, New York, Tennessee, Texas
2026-07-17
Recruiting
Novartis Pharmaceuticals
Phase 3
570
Arizona, Arkansas, California, Florida, Illinois, Massachusetts, Michigan, New Jersey
2026-07-16
Recruiting
Bayer
Observational
40
California, New Jersey
2026-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
134
California, Colorado, Florida, Iowa, Massachusetts, Michigan, Missouri, New Jersey
2026-07-06
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
Pfizer
Phase 2
40
California, Florida, Illinois, Massachusetts, New Jersey, New York, Ohio
2026-07-02
Recruiting
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07719361Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms
Flare Therapeutics Inc.
Phase 1
60
California, Massachusetts, Michigan, New Jersey, South Carolina, Tennessee, Texas
2026-07-01
Not yet open
Neurodawn Pharmaceutical Co., Ltd.
Phase 1
11
New Jersey
2026-06-30
Recruiting
EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
NCT07523581Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive
Eloxx Pharmaceuticals, Inc.
Phase 2
24
California, Colorado, Minnesota, New Jersey, Pennsylvania, Texas
2026-06-30
Recruiting
Novartis Pharmaceuticals
Observational
17,111
New Jersey
2026-06-30
Recruiting
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
NCT07488923Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC), Neuroendocrine Prostate Cancer (NEPC)
Moonlight Bio, Inc
Phase 1
110
Missouri, New Jersey, New York, Tennessee, Texas, Washington
2026-06-23
Recruiting
Theranica
Not applicable
120
New Jersey
2026-06-23
By invitation
Transcend Therapeutics
Phase 3
300
Arkansas, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Ohio
2026-06-22
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
960
California, Kentucky, New Jersey, New York, North Carolina, Ohio, Tennessee, Texas
2026-06-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Georgia, Illinois, Nebraska, New Jersey, New York, North Carolina, Virginia
2026-06-18
Recruiting
PleoPharma, Inc.
Phase 3
420
Arkansas, Connecticut, Florida, Georgia, Kentucky, Maryland, Nevada, New Jersey
2026-06-17
By invitation
Interference and Stability Evaluation of the Intelligent Fingerprinting Drug Screening System
NCT07758907Interference With Routine Analytical Tests, Stability of in Vitro Diagnostic Reagents, Illicit Drug Use
Intelligent Bio Solutions Inc.
Not applicable
95
New Jersey
2026-06-15
Recruiting
Gilead Sciences
Phase 2
175
Arizona, California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey
2026-06-15
Recruiting
Novartis Pharmaceuticals
Observational
4,023
New Jersey
2026-06-12
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
Takeda
Phase 2/3
500
California, Colorado, Florida, Georgia, Maryland, Michigan, Missouri, New Jersey
2026-06-11
Not yet open
Cell Free Preimplantation Genetic Testing
NCT04628507Infertility, Female, Infertility, Male
Genomic Prediction Inc.
Observational
200
New Jersey
2026-06-11
Recruiting
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
NCT07484022Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
Generate Biomedicines
Phase 1
37
California, Florida, Georgia, Illinois, New Jersey, New York, Texas, Virginia
2026-06-08
Recruiting
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
NCT07629960Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Blueprint Medicines Corporation
Phase 1/2
265
Florida, Louisiana, Massachusetts, Michigan, New Jersey, New York, Tennessee, Texas
2026-06-04
Recruiting
Bayer
Observational
3,000
New Jersey
2026-06-04
Recruiting
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia
NCT07732907Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy
Bristol-Myers Squibb
Observational
15
New Jersey
2026-06-04
Recruiting
Intelligent Bio Solutions Inc.
Observational
144
New Jersey
2026-06-02
Recruiting
Adverum Biotechnologies, Inc.
Phase 2
15
Arizona, California, Florida, Hawaii, Illinois, New Jersey, South Carolina, Texas
2026-06-02
Recruiting
Gilead Sciences
Phase 1
174
Massachusetts, Michigan, New Jersey, New York, Texas
2026-06-02
Not yet open
Insight Molecular Diagnostics
Observational
5,000
New Jersey
2026-06
Recruiting
Nyxoah Inc.
Observational
229
Florida, New Jersey
2026-06
Recruiting
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
NCT07542704Advanced Solid Tumors, Colorectal Cancer (CRC), Non-Small Cell Lung Cancer, Uterine Cancer
Kumquat Biosciences Inc.
Phase 1
48
California, Massachusetts, Michigan, New Jersey, New York, Ohio, Oregon, Pennsylvania
2026-05-27
Recruiting
Noom Inc.
Observational
2,541
New Jersey
2026-05-26
Recruiting
Hoffmann-La Roche
Phase 2/3
650
Alabama, Arizona, California, Connecticut, Michigan, New Jersey, New York, Tennessee
2026-05-21
By invitation
ID-ENTITY Trial- Evaluating Serial T-ID Monitoring
NCT07393594Kidney Diseases, Kidney Injury, BK Virus Infection, CMV
Transplant Genomics, Inc.
Observational
1,000
Arizona, California, Kansas, Michigan, New Hampshire, New Jersey, New York, North Carolina
2026-05-19
Recruiting
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
NCT07278479Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC)
Molecular Partners AG
Phase 1/2
138
Florida, Georgia, Illinois, Maryland, Nebraska, New Jersey, Ohio, Texas
2026-05-18
Recruiting
AstraZeneca
Phase 1/2
42
Florida, New Jersey, Rhode Island
2026-05-18
Recruiting
Janssen Research & Development, LLC
Phase 1
320
Indiana, Michigan, New Jersey, New York, Tennessee, Texas
2026-05-13
Recruiting
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
NCT07296744Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support
Supira Medical
Not applicable
358
California, Florida, Georgia, Illinois, Michigan, Minnesota, Missouri, New Jersey
2026-05-11
Active, closed
Eisai Inc.
Observational
600
New Jersey
2026-05-11
Active, closed
Relative Bioavailability Study of HNC364 Injectable Suspension
NCT06798519Parkinson's Disease (PD)
Guangzhou Henovcom Bioscience Co. Ltd.
Phase 1
30
New Jersey
2026-05-08
Recruiting
Ascendis Pharma Bone Diseases A/S
Phase 3
36
Colorado, Illinois, Minnesota, Nevada, New Jersey, New York, North Carolina, Texas
2026-05-07
Recruiting
Boehringer Ingelheim
Phase 1
60
Connecticut, New Jersey, New York, Tennessee
2026-05-01
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Novartis Pharmaceuticals
Phase 2
50
Illinois, New Jersey, New York, Ohio, Washington
2026-04-28
Recruiting
Curis, Inc.
Phase 2
108
Florida, Minnesota, New Jersey, Ohio, Pennsylvania, Texas
2026-04-23
Recruiting
Minerva Neurosciences
Phase 3
380
California, Florida, Georgia, Maryland, New Jersey, New York, Texas
2026-04-23
Recruiting
A Study to Evaluate the Efficacy and Safety of TP-06 for PCED
NCT07886268Persistent Corneal Epithelial Defect
Tarsus Pharmaceuticals, Inc.
Phase 2
32
Arizona, Florida, Georgia, Minnesota, New Jersey, New York, South Carolina, Texas
2026-04-20
Recruiting
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 3
420
Arizona, California, Florida, Maryland, New Jersey, Ohio, Oregon, Pennsylvania
2026-04-17
Recruiting
Visugromab in Cachexia International Trial
NCT07112196Cancer-associated Cachexia
CatalYm GmbH
Phase 2/3
518
Connecticut, Florida, Georgia, New Jersey, Ohio
2026-04-16
By invitation
Biogen
Phase 3
201
California, Minnesota, Missouri, Nebraska, New Jersey, Ohio, Pennsylvania, Virginia
2026-04-16
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
150
California, Florida, Illinois, Iowa, Mississippi, Nebraska, New Jersey, New York
2026-04-16
Active, closed
P-wave Duration and Local Potential as Predictors of AF Recurrence Following Pulmonary Vein Isolation
NCT07471308Atrial Fibrillation (AF), Atrial Fibrillation Patients Treated With the FARAPULSE™ PFA System, Atrial Fibrillation (Paroxysmal), Pulmonary Vein Isolation
CathVision ApS
Observational
300
New Jersey
2026-04-13
Recruiting
BeOne Medicines
Phase 1
84
Massachusetts, Missouri, New Jersey, Texas
2026-04-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
California, Georgia, Kentucky, Massachusetts, Michigan, Missouri, New Jersey, New York
2026-04-09
Recruiting
Novartis Pharmaceuticals
Observational
7,466
New Jersey
2026-04-08
Recruiting
Pfizer
Phase 3
1,712
Maine, Massachusetts, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Virginia
2026-04-08
Recruiting
A Gaucher Disease Gene Therapy Trial With FLT201
NCT07223944Gaucher Disease Type 1
Spur Therapeutics
Phase 3
45
California, Colorado, Georgia, Iowa, Minnesota, New Jersey, New York, North Carolina
2026-04-07
Recruiting
Diakonos Oncology Corporation
Phase 1/2
35
Alabama, Arizona, California, Massachusetts, New Jersey, North Carolina, Texas
2026-04-06
Recruiting
Biosense Webster, Inc.
Not applicable
566
Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Michigan, New Jersey
2026-04-02
Recruiting
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
NCT07462377Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell
EpiBiologics
Phase 1
110
California, New Jersey, New York, Tennessee, Texas
2026-03-31
Recruiting
Gilead Sciences
Phase 1/2
72
California, New Jersey, New York
2026-03-30
Recruiting
Vanda Pharmaceuticals
Phase 3
280
California, Florida, New Jersey, New York, Texas, Virginia
2026-03-27
Recruiting
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
NCT07144319Bladder Cancer, Non-muscle Invasive Bladder Cancer
Photocure
Observational
500
Florida, Iowa, Michigan, New Jersey, Tennessee
2026-03-25
Recruiting
Zenas BioPharma (USA), LLC
Phase 3
705
Arizona, California, Florida, Kansas, Missouri, New Jersey, North Carolina, Ohio
2026-03-23
Recruiting
IDEAYA Biosciences
Phase 1
155
California, Connecticut, Florida, Georgia, Missouri, New Jersey, New York, Tennessee
2026-03-17
Active, closed
Novaliq GmbH
Phase 2
20
Arizona, Florida, Massachusetts, New Jersey, Texas, Virginia
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 1/2
198
California, Illinois, Michigan, New Jersey, New York, Oregon, Tennessee, Washington
2026-03-16
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
Arkansas, California, Illinois, Indiana, Kansas, Michigan, Minnesota, New Jersey
2026-03-12
Recruiting
HeartFlow, Inc.
Observational
5,000
California, Florida, Georgia, Illinois, Kentucky, Michigan, Minnesota, New Jersey
2026-03-11
Recruiting
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
NCT07424833Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Ascentage Pharma Group Inc.
Phase 1
180
California, Florida, Michigan, New Jersey, Texas
2026-03-10
Active, closed
Tarsus Pharmaceuticals, Inc.
Phase 2
722
Maryland, Massachusetts, Minnesota, New Jersey, New York, Pennsylvania, Rhode Island
2026-03-09
Recruiting
Novartis Pharmaceuticals
Phase 2
272
California, Florida, Louisiana, Massachusetts, New Jersey, New York, Pennsylvania, Texas
2026-03-09
Recruiting
Janssen Research & Development, LLC
Phase 3
600
California, Colorado, Florida, Georgia, Illinois, Louisiana, Michigan, New Jersey
2026-03-05
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 4
75
Illinois, New Jersey, North Carolina, Tennessee
2026-03-04
Recruiting
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
NCT07277413Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Non-Small Cell Lung Cancer NSCLC
DrugIDE397
IDEAYA Biosciences
Phase 1
570
Arizona, California, District of Columbia, Florida, Illinois, Minnesota, Nebraska, New Jersey
2026-03-04
Recruiting
Arcutis Biotherapeutics, Inc.
Phase 1
125
Florida, Indiana, New Jersey, Texas, Utah
2026-03-02
Recruiting
Shanghai World Leader Pharmaceutical Co., Ltd.
Phase 1
60
New Jersey
2026-03-02
Recruiting
Sirt3 LLC
Not applicable
100
New Jersey
2026-03-01
Recruiting
COPD Exacerbation Follow Up
NCT07118306COPD (Chronic Obstructive Pulmonary Disease)
Viz.ai, Inc.
Observational
485
Illinois, New Jersey, Pennsylvania, Virginia, Wisconsin
2026-02-27
Recruiting
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
IDEAYA Biosciences
Phase 1
150
California, Colorado, Connecticut, Florida, Michigan, New Jersey, New York, Tennessee
2026-02-24
Active, closed
Pfizer
Phase 3
1,078
California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska, New Jersey
2026-02-24
Recruiting
Hoffmann-La Roche
Phase 2
80
California, Florida, Missouri, New Jersey
2026-02-18
Recruiting
Amplified Sciences Inc
Observational
50
Indiana, Massachusetts, New Jersey
2026-02-17
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1/2
428
Florida, New Jersey, New York, Tennessee, Virginia
2026-02-05
Recruiting
AI-Spectral
Observational
1,000
New Jersey
2026-02-01
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
Pfizer
Phase 1/2
162
Arkansas, California, Colorado, Florida, Massachusetts, New Jersey, New York, Oregon
2026-01-30
Recruiting
Genmab
Phase 2
240
California, District of Columbia, Florida, Georgia, Montana, Nebraska, New Jersey, New York
2026-01-30
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC
Revolution Medicines, Inc.
Phase 1/2
370
Arizona, California, Connecticut, Kentucky, Minnesota, Missouri, New Jersey, New York
2026-01-30
Active, closed
Praxis Precision Medicines
Phase 3
300
Florida, New Jersey, New York, North Carolina, Texas
2026-01-29
Recruiting
Bristol-Myers Squibb
Phase 3
166
California, Florida, Georgia, Illinois, Massachusetts, New Jersey, New York, Ohio
2026-01-29
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
170
California, Colorado, Florida, Kentucky, Missouri, New Jersey, Oregon, South Dakota
2026-01-29
Active, closed
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
NCT07363720Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
Takeda
Phase 3
98
California, Florida, Michigan, New Jersey, North Carolina, Ohio, South Carolina, Texas
2026-01-29
Recruiting
Dentsply Sirona Implants and Consumables
Not applicable
90
California, New Jersey, North Carolina, Texas
2026-01-29
Active, closed
Pacagen, Inc.
Not applicable
190
New Jersey, Virginia
2026-01-26
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.
Phase 2/3
153
California, Illinois, Massachusetts, Michigan, Minnesota, New Jersey, New York, Pennsylvania
2026-01-22
Recruiting
Sanofi
Phase 3
100
Georgia, Nebraska, New Jersey, Texas
2026-01-20
Recruiting
Bristol-Myers Squibb
Phase 4
60
Arkansas, California, Florida, Illinois, Nevada, New Jersey, Pennsylvania, Texas
2026-01-20
Recruiting
Eikon Therapeutics
Phase 1/2
160
California, Florida, New Jersey, New York, Texas
2026-01-20
Recruiting
Novartis Pharmaceuticals
Observational
350
New Jersey
2026-01-17
Recruiting
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
NCT07049055Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
Engeneic Pty Limited
Phase 1/2
144
California, New Jersey, New York, Ohio
2026-01-12
Recruiting
Alnylam Pharmaceuticals
Observational
2,000
Arizona, California, Florida, Hawaii, Kansas, Massachusetts, Missouri, New Jersey
2026-01-09
Recruiting
Bionic Sight LLC
Phase 1/2
40
New Jersey
2026-01-08
Active, closed
Theranica
Phase 4
2,000
New Jersey
2026-01-08
Recruiting
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
NCT07224581GRIN-related Neurodevelopmental Disorder
GRIN Therapeutics, Inc.
Phase 3
100
California, Colorado, District of Columbia, Florida, Iowa, Massachusetts, New Jersey, New York
2026-01-05
By invitation
Novo Nordisk A/S
Observational
93,600,000
New Jersey
2025-12-31
Recruiting
Neurocrine Biosciences
Phase 2
150
Arkansas, California, Florida, Georgia, Maryland, New Jersey, New York, Texas
2025-12-24
Recruiting
Taiho Oncology, Inc.
Phase 3
360
Alaska, California, District of Columbia, Florida, Georgia, Illinois, Michigan, New Jersey
2025-12-22
Recruiting
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
NCT07444814Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent
Whitehawk Therapeutics, Inc.
Phase 1
226
Alabama, Arizona, Arkansas, California, Illinois, Maryland, Michigan, New Jersey
2025-12-19
Recruiting
Merck Sharp & Dohme LLC
Phase 1
250
New Jersey, Texas, Virginia
2025-12-16
Recruiting
Hutchmed
Phase 1/2
147
Colorado, Florida, New Jersey, New York, Ohio, Washington
2025-12-16
Recruiting
Neurocrine Biosciences
Phase 3
560
California, Florida, Georgia, Massachusetts, Mississippi, New Jersey, New York, Texas
2025-12-16
Recruiting
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
NCT06323447Diffuse Large B Cell Lymphoma, Multiple Myeloma
Leuko Labs, Inc.
Observational
210
Hawaii, Kentucky, Massachusetts, New Jersey, Texas
2025-12-15
Recruiting
GlaxoSmithKline
Phase 3
1,250
California, Florida, Kansas, Louisiana, Missouri, New Jersey, New York, North Carolina
2025-12-12
Recruiting
Merck Sharp & Dohme LLC
Phase 2
180
Florida, Michigan, Missouri, New Jersey, New York, Ohio, Oregon, Tennessee
2025-12-12
Recruiting
TuHURA Biosciences, Inc.
Phase 2/3
118
California, Colorado, Florida, Massachusetts, Minnesota, New Jersey, North Carolina, Pennsylvania
2025-12-11
Recruiting
UCB Biopharma SRL
Phase 1
392
Arizona, California, Colorado, Florida, Illinois, Michigan, New Jersey, New Mexico
2025-12-10
Recruiting
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
NCT07222488Bladder Cancer, Urinary Bladder Neoplasms
Merck Sharp & Dohme LLC
Phase 1/2
45
California, New Jersey, South Carolina, Texas
2025-12-09
Recruiting
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT07216443Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia
DrugOrca-T
Orca Biosystems, Inc.
Phase 2
130
California, Colorado, Florida, Minnesota, New Jersey, New York, Oregon, Tennessee
2025-12-09
Recruiting
Novartis Pharmaceuticals
Observational
100
New Jersey
2025-12-08
Recruiting
Cellectar Biosciences, Inc.
Phase 1
60
Florida, Maryland, Minnesota, New Jersey
2025-12-05
By invitation
Study on Home Obstructive Respiratory Exacerbations
NCT06544928COPD Exacerbation, COPD (Chronic Obstructive Pulmonary Disease) With Acute Lower Respiratory Infection, COPD Exacerbation Acute, COPD
Strados Labs, Inc.
Observational
20
New Jersey
2025-12-05
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
Maryland, Michigan, Nevada, New Jersey, Utah, Virginia
2025-12-04
Recruiting
Cayuga Biotech, Inc.
Phase 1
24
New Jersey
2025-12-02
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Arizona, California, Connecticut, Florida, Indiana, Louisiana, New Jersey, North Carolina
2025-11-25
Active, closed
REGENXBIO Inc.
Phase 3
2
New Jersey
2025-11-25
Recruiting
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
NCT07261631Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
180
New Jersey
2025-11-24
Active, closed
Pfizer
Phase 3
207
New Jersey, New York, Pennsylvania
2025-11-19
Recruiting
Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure
NCT07209098Heart Failure and Reduced Ejection Fraction, NYHA Class III Heart Failure
Impulse Dynamics
Observational
4,200
New Jersey
2025-11-18
Recruiting
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
NCT07192432HER2 Expressing Solid Tumors
Vironexis Biotherapeutics Inc.
Phase 1/2
27
California, Colorado, Florida, Minnesota, New Jersey, New York, Ohio, Pennsylvania
2025-11-18
Active, closed
Eisai Inc.
Observational
170
New Jersey
2025-11-17
Active, closed
Eli Lilly and Company
Phase 3
250
California, Florida, Illinois, Kentucky, Louisiana, Maryland, Missouri, New Jersey
2025-11-17
Recruiting
Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers
NCT07396376Diabetic Foot Ulcer, Wagner Grade 1 - 2, Chronic Wound, Open Wound
Eluciderm Inc
Phase 1/2
15
Illinois, New Jersey, Texas
2025-11-10
Active, closed
Novartis Pharmaceuticals
Phase 2
34
California, Maryland, New Jersey
2025-11-10
Recruiting
Pfizer
Phase 1
294
Alabama, Florida, Georgia, Illinois, Iowa, Kansas, New Jersey, New York
2025-11-06
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
65
Colorado, Florida, Illinois, Massachusetts, Missouri, New Jersey, New York, Ohio
2025-11-06
Active, closed
Vasa Therapeutics
Phase 1
42
Arkansas, California, Florida, Illinois, Louisiana, Missouri, New Jersey, New York
2025-11-04
Active, closed
Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07214961Prostate Cancer (CRPC), Metastatic Castrate Resistant Prostate Cancer (mCRPC)
ARTBIO Inc.
Phase 1
80
Michigan, Nebraska, New Jersey
2025-11-03
Recruiting
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT07182149HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Normunity AccelCo, Inc.
Phase 1
150
Colorado, Connecticut, District of Columbia, Massachusetts, Minnesota, Missouri, New Jersey, Ohio
2025-10-30
Recruiting
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
NCT07332000Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
Candel Therapeutics, Inc.
Phase 2
45
Arizona, Colorado, Maryland, Nevada, New Jersey, South Carolina
2025-10-30
Active, closed
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
NCT07217860Bipolar Depression, Bipolar I Disorder, Bipolar Disorder, Bipolar II Disorder
Xenon Pharmaceuticals Inc.
Phase 3
400
Arkansas, California, Florida, Georgia, Illinois, New Jersey, New York, Pennsylvania
2025-10-30
Recruiting
Novartis Pharmaceuticals
Phase 2
165
Mississippi, New Jersey, New York, North Carolina, Utah, Washington
2025-10-28
Recruiting
Novartis Pharmaceuticals
Phase 3
12
Georgia, New Jersey, Pennsylvania, Tennessee
2025-10-28
By invitation
Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
NCT07287163Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
Praxis Precision Medicines
Phase 3
700
Florida, Louisiana, Maryland, Michigan, Missouri, New Jersey, New York, Pennsylvania
2025-10-27
Recruiting
Takeda
Phase 3
70
Arizona, California, Illinois, Michigan, New Jersey, New York, Ohio, Oklahoma
2025-10-27
Recruiting
Criterium, Inc.
Phase 2
120
Connecticut, Florida, New Jersey, New York, Pennsylvania, South Carolina, Tennessee, Texas
2025-10-27
Recruiting
The HEARTFELT Study
NCT06222099Heart Failure, Chronic Heart Failure
Heartfelt Technologies
Not applicable
1,500
Arkansas, Florida, New Jersey, Pennsylvania
2025-10-23
Recruiting
A Study of ZW251 in Participants With Advanced Solid Tumors
NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
Zymeworks BC Inc.
Phase 1
140
California, Kentucky, Michigan, New Jersey, New York, Texas
2025-10-21
Active, closed
Eli Lilly and Company
Phase 2
200
Arizona, Florida, Georgia, Nevada, New Jersey, Ohio, Texas, Utah
2025-10-16
Active, closed
Genentech, Inc.
Phase 1
60
California, Missouri, New Jersey, New York
2025-10-15
By invitation
AccurKardia, Inc.
Observational
50
New Jersey
2025-10-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
300
California, Connecticut, Florida, Georgia, Maryland, New Jersey, Oklahoma, Pennsylvania
2025-10-09
Recruiting
AbbVie
Phase 1
52
California, Florida, Illinois, New Jersey
2025-10-08
Recruiting
Bristol-Myers Squibb
Observational
223
California, Florida, Georgia, Illinois, Maryland, Michigan, Montana, New Jersey
2025-10-08
Recruiting
Luminate Medical, Inc.
Not applicable
142
California, Connecticut, Florida, Hawaii, Illinois, Indiana, Minnesota, New Jersey
2025-10-03
Recruiting
Ponce Medical School Foundation, Inc.
Not applicable
125
New Jersey, New York
2025-10-01
Not yet open
COSMO ROBOTICS CO., Ltd
Not applicable
20
New Jersey
2025-10
Recruiting
Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome
NCT06776783Respiratory Distress Syndrome, Pre-term Infants
Aerogen Pharma Limited
Phase 3
520
Arkansas, California, Florida, Indiana, Maryland, Massachusetts, New Jersey, New York
2025-09-24
Recruiting
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
NCT07140016Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
Astellas Pharma Global Development, Inc.
Phase 1
40
California, Colorado, Georgia, Illinois, Michigan, Missouri, New Jersey, Texas
2025-09-22
Recruiting
MMI (Medical Microinstruments, Inc.)
Observational
455
California, Connecticut, Florida, New Jersey, New York, Ohio, South Carolina
2025-09-22
Recruiting
Bristol-Myers Squibb
Observational
300
California, Florida, Illinois, Maryland, Massachusetts, Nebraska, New Jersey, New York
2025-09-22
Recruiting
Phagenyx® Registry Study
NCT06866418Dysphagia
Phagenesis Ltd.
Observational
600
Arizona, New Jersey, Texas
2025-09-15
Recruiting
CSL Behring
Phase 3
200
California, Georgia, Illinois, Kansas, Maryland, New Jersey, New York, Ohio
2025-09-15
Active, closed
A Study in Subjects With Neurogenic Orthostatic Hypotension
NCT07089043Neurogenic Orthostatic Hypotension
CuraSen Therapeutics, Inc.
Phase 2
12
Arizona, Michigan, New Jersey, New York, Tennessee
2025-09-12
Recruiting
A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
NCT07205887Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
EyeBiotech Ltd.
Phase 2
160
Arizona, California, Colorado, Florida, Illinois, Maryland, Mississippi, New Jersey
2025-09-12
Recruiting
Lumbar & Sacroiliac Fusion Study Involving Previously Implanted Devices
NCT07204288Fusion of Spine, Sacroiliac; Fusion
Spinal Simplicity LLC
Observational
500
Kansas, Minnesota, New Jersey, Oklahoma, West Virginia
2025-09-11
Recruiting
Bristol-Myers Squibb
Phase 1
131
California, Florida, Georgia, Illinois, New Jersey, Texas
2025-09-03
Recruiting
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
NCT07145255Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell)
MBrace Therapeutics
Phase 1/2
150
California, Michigan, New Jersey, Texas, Utah, Virginia
2025-09-03
Active, closed
Daiichi Sankyo
Observational
760
New Jersey
2025-09-01
Recruiting
Gilead Sciences
Phase 1
476
Massachusetts, New Jersey, Texas, Virginia
2025-08-28
Recruiting
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
NCT07169734Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma
Alentis Therapeutics AG
Phase 1/2
180
Arizona, California, Connecticut, Illinois, Kentucky, New Jersey, Texas, Virginia
2025-08-26
Recruiting
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
NCT07085091NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
ALX Oncology Inc.
Phase 1
170
California, Florida, Michigan, New Jersey, Ohio, Oregon, Texas, Utah
2025-08-18
Recruiting
Wayshine Biopharm, Inc.
Phase 2
40
Florida, New Jersey, Ohio, Pennsylvania, Virginia
2025-08-18
Recruiting
Exelixis
Phase 1
150
Arkansas, California, District of Columbia, Florida, Michigan, New Jersey, North Carolina, Texas
2025-08-18
Recruiting
MapLight Therapeutics
Phase 2
300
Arizona, California, Colorado, Florida, Georgia, Louisiana, Nevada, New Jersey
2025-08-15
Recruiting
GlaxoSmithKline
Phase 2
220
Florida, New Jersey, New York, North Carolina, Oklahoma, Texas, Virginia
2025-08-14
Recruiting
Merck Sharp & Dohme LLC
Phase 2
250
Alaska, Florida, Louisiana, Nebraska, New Jersey, New York, Ohio, Texas
2025-08-11
Recruiting
AbbVie
Phase 2
268
Arkansas, California, Maryland, New Jersey, Texas
2025-08-04
Recruiting
AbbVie
Phase 2
377
California, Colorado, Minnesota, New Jersey, New York, Ohio, Oklahoma, Oregon
2025-07-30
Active, closed
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
SystImmune Inc.
Phase 1
160
Arizona, California, Colorado, Connecticut, Louisiana, Michigan, New Jersey, Tennessee
2025-07-30
Active, closed
Bausch & Lomb Incorporated
Phase 1
24
New Jersey
2025-07-29
Recruiting
AbbVie
Phase 3
120
Arizona, California, Florida, Georgia, Illinois, New Jersey, Ohio, Pennsylvania
2025-07-28
Active, closed
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 1
240
California, Florida, Illinois, Indiana, Massachusetts, Missouri, New Jersey, New York
2025-07-28
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Astellas Pharma Inc
Phase 1
404
California, Georgia, Louisiana, Michigan, Missouri, New Jersey, New York, Ohio
2025-07-25
Recruiting
Pharmazz, Inc.
Phase 3
514
Arizona, California, Florida, Georgia, Missouri, New Jersey, North Carolina, Ohio
2025-07-24
Recruiting
Merck Sharp & Dohme LLC
Phase 1
67
Illinois, New Jersey, Texas
2025-07-23
Recruiting
SpotitEarly
Observational
1,204
New Jersey, Pennsylvania
2025-07-22
Recruiting
CSL Behring
Observational
200
Arizona, Florida, Illinois, Kentucky, Maryland, Missouri, New Jersey
2025-07-21
Recruiting
Daiichi Sankyo
Phase 2
130
Alabama, California, Maryland, Massachusetts, New Jersey, New York, North Carolina, Pennsylvania
2025-07-18
Recruiting
Merck Sharp & Dohme LLC
Phase 2
340
California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2025-07-16
Recruiting
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
NCT07075185Multiple Myeloma in Relapse, Myeloma Multiple, Multiple Myeloma Progression, Neoplasms by Histologic Type
Kelonia Therapeutics, Inc.
Phase 1
70
California, Florida, Georgia, Massachusetts, New Jersey, Oregon
2025-07-16
Not yet open
Olly, PBC
Not applicable
80
New Jersey
2025-07-15
Active, closed
Praxis Precision Medicines
Phase 3
160
California, Florida, Maryland, Minnesota, New Jersey, Pennsylvania
2025-07-09
Recruiting
CorMedix Therapeutics
Phase 4
36
Alabama, Arizona, California, Delaware, New Jersey, Texas
2025-07-08
Recruiting
Krystal Biotech, Inc.
Phase 1/2
60
California, Indiana, Minnesota, Missouri, New Jersey, North Dakota, Pennsylvania
2025-07-07
Recruiting
Study With Phage for CF Subjects With Pseudomonas Lung Infection
NCT06998043Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
BiomX Ltd
Phase 2
63
Alabama, Alaska, Arkansas, California, Colorado, Florida, New Jersey, New York
2025-07-02
Recruiting
Soterix Medical
Not applicable
25
New Jersey
2025-07-01
Recruiting
Centessa Pharmaceuticals (UK) Limited
Phase 1
208
Nebraska, New Jersey, New York
2025-06-30
Recruiting
Pulmotect, Inc.
Phase 2
100
California, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York
2025-06-27
Recruiting
Regeneron Pharmaceuticals
Phase 3
2,000
Alabama, California, Colorado, Florida, Maryland, Massachusetts, New Jersey, North Carolina
2025-06-25
Recruiting
Enterra Medical, Inc.
Not applicable
148
Arizona, California, Florida, Illinois, Indiana, Kentucky, New Jersey, Ohio
2025-06-23
Active, closed
jCyte, Inc
Phase 2
31
Arizona, California, Florida, Illinois, New Jersey, New York, Texas, Virginia
2025-06-20
Recruiting
Perosphere Technologies Inc.
Observational
150
Connecticut, Maryland, New Jersey, New York
2025-06-20
Recruiting
Stryker Neurovascular
Not applicable
183
Arizona, California, Florida, Indiana, Iowa, Kansas, Massachusetts, New Jersey
2025-06-20
Recruiting
Biocomposites Ltd
Phase 2
60
Arizona, Illinois, Michigan, Mississippi, Missouri, Nebraska, New Jersey, New York
2025-06-15
Recruiting
Signum Surgical USA Inc.
Observational
50
Florida, New Jersey, New York, Pennsylvania
2025-06-14
Recruiting
GlaxoSmithKline
Phase 1/2
85
Arizona, Colorado, Connecticut, Minnesota, New Jersey, Tennessee
2025-06-12
Recruiting
ImmVira Pharma Co. Ltd
Phase 2
160
Arizona, California, Florida, New Jersey, Ohio, Pennsylvania, South Carolina
2025-06-09
Recruiting
MediWound Ltd
Phase 3
216
Arizona, California, District of Columbia, Florida, Massachusetts, New Jersey, New York, Ohio
2025-06-01
Recruiting
W.L.Gore & Associates
Observational
158
Alabama, California, Florida, Minnesota, New Jersey, New York, North Carolina, Ohio
2025-05-30
Recruiting
Neurocrine Biosciences
Phase 3
200
California, Colorado, Connecticut, Florida, Illinois, Maryland, Nevada, New Jersey
2025-05-30
Active, closed
Merck Sharp & Dohme LLC
Phase 2
160
Arkansas, California, New Jersey, Virginia, Washington
2025-05-29
Recruiting
Eisai Inc.
Observational
6,700
New Jersey
2025-05-23
Recruiting
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
NCT06271590Coronary Artery Disease, Native Coronary Artery Stenosis, Cardiovascular Diseases
Concept Medical Inc.
Not applicable
1,605
Arizona, California, Florida, Georgia, Illinois, Mississippi, New Jersey, New York
2025-05-20
Recruiting
SLV-154 Treatment of Advanced Cancers
NCT06771219Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer
Solve Therapeutics
Phase 1
250
California, Missouri, New Jersey, New York, Ohio, Pennsylvania, Texas, Washington
2025-05-14
Recruiting
Neurocrine Biosciences
Phase 3
284
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, New Jersey
2025-05-08
Recruiting
BioNTech SE
Phase 1/2
594
Arizona, California, Colorado, Florida, Iowa, Minnesota, New Jersey, New York
2025-05-02
Recruiting
SPYRAL GEMINI Pilot Study
NCT06907147Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
175
California, Florida, Georgia, Massachusetts, Michigan, Mississippi, Nevada, New Jersey
2025-05-01
Recruiting
Pacific Edge Limited
Not applicable
1,000
Alabama, California, Florida, Indiana, Louisiana, Maryland, New Jersey, New York
2025-04-29
Active, closed
Synthekine
Phase 1
48
Arizona, New Jersey, New York, Ohio
2025-04-29
Recruiting
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
NCT07080242Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer, Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
SystImmune Inc.
Phase 1
120
Alabama, California, Colorado, Connecticut, Georgia, Louisiana, New Jersey, New York
2025-04-28
Recruiting
BioNTech SE
Phase 1/2
380
California, Florida, Georgia, Illinois, Michigan, Missouri, New Jersey, New York
2025-04-23
Active, closed
Regeneron Pharmaceuticals
Phase 2
28
California, Colorado, Kansas, Michigan, New Jersey, Tennessee, Texas, Virginia
2025-04-14
Recruiting
Bristol-Myers Squibb
Phase 3
194
California, Florida, Illinois, Kentucky, New Jersey, Ohio, Oregon, Texas
2025-04-08
Recruiting
Home Reported Outcomes in C3G Study
NCT07029542C3 Glomerulopathy
Novartis Pharmaceuticals
Observational
100
New Jersey
2025-04-07
Not yet open
Below-the-Knee Interventions for Limb Salvage: Use of Multifunctional Angioplasty Balloon Catheters
NCT06906055Peripheral Arterial Disease Below the Knee, Peripheral Arterial Disease, Rutherford 4 and 5 with Possibility to Improve Vascularization
Summa Therapeutics, LLC
Not applicable
24
Delaware, New Jersey
2025-04-03
Active, closed
Merck Sharp & Dohme LLC
Phase 2
160
Connecticut, District of Columbia, Florida, Montana, New Jersey, Ohio, Virginia, Wisconsin
2025-04-01
Active, closed
Hoffmann-La Roche
Phase 2
162
California, Florida, Georgia, Indiana, Michigan, Minnesota, New Jersey, Ohio
2025-04-01
Active, closed
Autobahn Therapeutics, Inc.
Phase 2
35
California, Connecticut, Florida, Illinois, Massachusetts, New Jersey, New York, Washington
2025-03-28
Recruiting
Eli Lilly and Company
Phase 2
200
Arizona, California, Florida, Georgia, Idaho, Indiana, New Jersey, New York
2025-03-28
Recruiting
AstraZeneca
Phase 1/2
304
California, Maryland, Massachusetts, Missouri, New Jersey, Texas
2025-03-27
Active, closed
Incyte Corporation
Phase 1
30
California, Colorado, District of Columbia, Florida, Maryland, New Jersey, Pennsylvania, Tennessee
2025-03-27
Recruiting
Daiichi Sankyo
Phase 3
510
Arizona, California, Michigan, Minnesota, Missouri, New Jersey, New York, Pennsylvania
2025-03-27
Active, closed
MiRus
Not applicable
30
California, Florida, Georgia, Minnesota, New Jersey, New York, Ohio
2025-03-26
Recruiting
Bristol-Myers Squibb
Phase 1
437
New Jersey, Pennsylvania, Tennessee, Texas
2025-03-25
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
270
Alabama, Florida, New Jersey, Texas, Virginia
2025-03-25
Recruiting
Diakonos Oncology Corporation
Phase 2
180
Arizona, California, Florida, Massachusetts, New Jersey, New York, North Carolina, Ohio
2025-03-17
Active, closed
Averitas Pharma, Inc.
Observational
144
Delaware, Georgia, Kentucky, New Jersey, Ohio, Pennsylvania
2025-03-14
Active, closed
Hoffmann-La Roche
Phase 4
274
California, Florida, Illinois, Massachusetts, Nevada, New Jersey, New Mexico, Tennessee
2025-03-14
Recruiting
Moleculin Biotech, Inc.
Phase 2/3
312
Alabama, Florida, Georgia, Nebraska, New Jersey, Ohio, Pennsylvania, Rhode Island
2025-03-12
Active, closed
Vir Biotechnology, Inc.
Phase 3
124
Arizona, California, Florida, Illinois, Maryland, New Jersey, New York, Utah
2025-03-12
Active, closed
AstraZeneca
Phase 2
82
Arizona, California, District of Columbia, Maryland, Massachusetts, Minnesota, New Jersey, New York
2025-03-12
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
Alexion Pharmaceuticals, Inc.
Phase 2
47
Alabama, Arizona, California, Florida, Georgia, Kansas, Michigan, New Jersey
2025-03-07
Active, closed
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
NCT06521567Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM)
GlaxoSmithKline
Phase 1/2
83
California, Iowa, New Jersey, Ohio, Rhode Island, Wisconsin
2025-03-06
Active, closed
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
NCT06845202Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
Alnylam Pharmaceuticals
Phase 1/2
105
California, District of Columbia, Florida, New Jersey, North Carolina, Texas
2025-03-03
Active, closed
Voyager Therapeutics
Phase 1/2
52
California, Connecticut, Florida, Georgia, New Jersey, North Carolina, Pennsylvania
2025-03-03
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
538
Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland, New Jersey
2025-02-28
Recruiting
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma
Clasp Therapeutics, Inc.
Phase 1
90
Arizona, California, Florida, Illinois, Kentucky, Maryland, New Jersey, New York
2025-02-28
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
327
Colorado, Florida, Illinois, Massachusetts, New Jersey, New York, Oregon, Tennessee
2025-02-27
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Florida, Georgia, Louisiana, Massachusetts, New Jersey, New York, Tennessee, Texas
2025-02-26
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
181
Colorado, Massachusetts, New Jersey, South Carolina, Virginia
2025-02-26
Recruiting
Amgen
Phase 3
844
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Missouri, New Jersey
2025-02-25
Recruiting
Eisai Korea Inc.
Observational
3,000
New Jersey
2025-02-24
Recruiting
Bristol-Myers Squibb
Phase 1/2
286
California, Colorado, New Jersey, New York, North Carolina, Washington
2025-02-17
Recruiting
Online Evaluation of the Diagnostic Accuracy of BlinkLab's Digital Assessments for Autism
NCT07590973Autism, Autism Spectrum Disorder, Autism Spectrum Disorder (ASD), Neurodevelopmental Conditions
Blinklab Limited
Observational
1,000
New Jersey
2025-02-15
Active, closed
Bristol-Myers Squibb
Phase 1/2
360
California, Michigan, New Jersey, Pennsylvania
2025-02-12
Recruiting
Bristol-Myers Squibb
Phase 1/2
416
Alabama, Florida, Iowa, Missouri, New Jersey, Ohio, Oregon, Pennsylvania
2025-02-04
Recruiting
Sequenom, Inc.
Observational
6,550
Arizona, Delaware, Florida, Louisiana, Massachusetts, New Jersey, New York, North Carolina
2025-02-02
Recruiting
Integrity Implant System Post Market Clinical Follow-Up Study
NCT06741527Rotator Cuff Tears of the Shoulder
Anika Therapeutics, Inc.
Not applicable
150
Arizona, California, Florida, Georgia, Indiana, Maryland, New Jersey, South Carolina
2025-02-01
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
AstraZeneca
Phase 1/2
408
Massachusetts, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island
2025-01-30
Active, closed
Definium Therapeutics US, Inc.
Phase 3
245
Arkansas, California, Florida, Georgia, Maryland, Massachusetts, New Jersey, Ohio
2025-01-29
By invitation
Verismo Therapeutics
Observational
60
Colorado, Georgia, Kansas, New Jersey, Pennsylvania, Texas, Wisconsin
2025-01-27
Active, closed
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
NCT06781983Advanced or Metastatic Solid Tumors
Innate Pharma
Phase 1
145
Massachusetts, New Jersey, New York, Texas, Virginia
2025-01-24
Recruiting
Serranator POINT FORCE Registry
NCT06687590Peripheral Artery Disease (PAD), Dysfunctional AV Fistula, Dysfunctional AV Graft
Cagent Vascular LLC
Observational
500
Arizona, California, Connecticut, District of Columbia, Florida, Michigan, Missouri, New Jersey
2025-01-22
Recruiting
Takeda
Phase 3
70
Arizona, California, Illinois, Michigan, New Jersey, New York, Ohio, Oklahoma
2025-01-22
Recruiting
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
NCT06182397Arterial Disease of Legs, Below-the-knee Obstruction, PAD - Peripheral Arterial Disease
Concept Medical Inc.
Not applicable
368
Arizona, California, Florida, Iowa, Michigan, New Jersey, New York, Ohio
2025-01-16
Active, closed
Stemline Therapeutics, Inc.
Phase 2
85
California, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey, New York
2025-01-14
Recruiting
NGGT INC.
Phase 1/2
12
California, Minnesota, New Jersey, Pennsylvania, Texas
2025-01-10
Recruiting
Praxis Precision Medicines
Phase 2
50
Arizona, Florida, Maryland, Missouri, New Jersey, New York, Texas
2025-01-10
Recruiting
Fortvita Biologics (USA)Inc.
Phase 1
250
California, New Jersey, Texas, Virginia
2025-01-10
Recruiting
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963Ovarian Cancer, Breast Cancer, Endometrial Cancer, Non-Small Cell Lung Cancer
LigaChem Biosciences, Inc.
Phase 1
145
California, Kentucky, Massachusetts, Missouri, New Jersey, New York, Ohio, Pennsylvania
2025-01-07
Active, closed
Daiichi Sankyo
Phase 2
335
Georgia, Michigan, New Jersey, New York, Tennessee, Texas
2025-01-06
Active, closed
Bayer
Observational
10,000
New Jersey
2025-01-06
Active, closed
Eisai Inc.
Observational
861
New Jersey
2025-01-03
Active, closed
Zirconia Implants: Practice-based Evidence
NCT06314425Dental Implants, Ceramic Implant
Swiss Dental Solutions
Not applicable
50
New Jersey
2025-01-03
Recruiting
InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS
NCT05960929Respiratory Distress Syndrome (Neonatal), Intubation Complication, Death; Neonatal
ONY
Phase 3
220
Arizona, California, Florida, Hawaii, New Jersey, New York, Tennessee, Utah
2025-01-01
Recruiting
The Lily Device Trial
NCT06786078Chemotherapy Induced Alopecia
Luminate Medical, Inc.
Not applicable
85
New Jersey, New York, Pennsylvania
2024-12-20
Recruiting
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
NCT06747585Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
Alentis Therapeutics AG
Phase 1/2
235
Arizona, California, Connecticut, Illinois, Kentucky, New Jersey, Virginia
2024-12-16
Recruiting
The PERSEVERE Study
NCT06588634Pulmonary Embolism, Pulmonary Thromboembolism
Inari Medical
Not applicable
200
Connecticut, Florida, Georgia, Mississippi, New Jersey, New York, Ohio, Pennsylvania
2024-12-16
Active, closed
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
NCT06750432Alzheimer Disease, Early Onset
ProMis Neurosciences, Inc
Phase 1
144
California, Florida, Georgia, Massachusetts, New Jersey, New York, North Carolina, Ohio
2024-12-13
Active, closed
Definium Therapeutics US, Inc.
Phase 3
214
Arizona, California, Colorado, Florida, Georgia, Illinois, Massachusetts, New Jersey
2024-12-11
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 2
130
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New Jersey, New York
2024-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 2
120
Arizona, California, Georgia, Louisiana, Nevada, New Jersey, Texas, Wisconsin
2024-11-27
Recruiting
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
NCT06699056Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement
Peerbridge Health, Inc
Observational
2,000
California, Michigan, New Jersey, New York, North Carolina, Texas
2024-11-21
Recruiting
Stingray Therapeutics
Phase 2
70
New Jersey, Texas, Washington
2024-11-20
Active, closed
GlaxoSmithKline
Phase 1/2
465
Kansas, Louisiana, New Jersey, New York, Pennsylvania, Texas, Washington
2024-11-19
Active, closed
Pfizer
Phase 3
636
Arizona, California, Colorado, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2024-11-15
Recruiting
AbbVie
Phase 3
264
California, Colorado, Florida, Illinois, Maryland, Missouri, Nevada, New Jersey
2024-11-05
Recruiting
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
NCT06733935Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis
Nkarta, Inc.
Phase 1/2
240
California, Florida, Kansas, Michigan, Minnesota, New Jersey, New York, North Carolina
2024-11-04
Recruiting
SynKIR-310 for Relapsed/Refractory B-NHL
NCT06544265B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Verismo Therapeutics
Phase 1
36
Colorado, Georgia, Kansas, New Jersey, Pennsylvania
2024-11-01
Recruiting
Palette Life Sciences, Inc.
Not applicable
84
Arizona, California, Florida, Georgia, Massachusetts, New Jersey, Ohio, Pennsylvania
2024-10-31
Recruiting
Sanofi
Phase 1
87
Arizona, Florida, Minnesota, New Jersey, Pennsylvania
2024-10-30
Recruiting
Eli Lilly and Company
Phase 1
128
California, Florida, Georgia, Michigan, New Jersey, North Carolina
2024-10-29
Recruiting
Intra-Cellular Therapies, Inc.
Phase 2
320
California, Florida, Massachusetts, Nevada, New Jersey, North Carolina, Texas
2024-10-22
Recruiting
BeOne Medicines
Phase 1
153
New Jersey, Texas, Virginia, Wisconsin
2024-10-18
Active, closed
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
NCT06581575Herpes Zoster (HZ), Infectious Diseases, Shingles
Immorna Biotherapeutics, Inc.
Phase 2
467
Arizona, California, Illinois, Nebraska, New Jersey, South Carolina, Texas
2024-10-16
Active, closed
Ipsen
Observational
424
California, Colorado, Connecticut, Florida, Massachusetts, New Jersey, New York, North Carolina
2024-10-14
Recruiting
BeOne Medicines
Phase 1
310
Arizona, California, Colorado, Connecticut, Illinois, Kansas, Mississippi, New Jersey
2024-10-03
Recruiting
GlaxoSmithKline
Phase 1
845
California, Colorado, Connecticut, Indiana, Massachusetts, Michigan, New Jersey, South Carolina
2024-09-30
Recruiting
VIS, Inc.
Phase 3
75
Florida, Massachusetts, New Jersey, New York
2024-09-30
Active, closed
AstraZeneca
Phase 3
310
California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Oklahoma, Texas
2024-09-30
Recruiting
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
NCT06463665Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma
Genelux Corporation
Phase 2
142
Arizona, Florida, Michigan, New Jersey, Ohio, Texas
2024-09-26
Recruiting
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor
NiKang Therapeutics, Inc.
Phase 1
238
Arkansas, California, Colorado, Florida, Georgia, Kansas, Massachusetts, New Jersey
2024-09-19
Active, closed
argenx
Phase 3
141
Arizona, California, Florida, Illinois, Maryland, Massachusetts, Michigan, New Jersey
2024-09-18
Recruiting
AstraZeneca
Phase 1/2
174
California, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Texas, Washington
2024-09-18
Active, closed
Regeneron Pharmaceuticals
Phase 2
151
California, Colorado, Connecticut, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2024-09-18
Active, closed
Pfizer
Observational
300
Arizona, California, Colorado, Florida, Illinois, Maryland, New Jersey, New York
2024-09-17
Active, closed
GlaxoSmithKline
Phase 2
153
California, Florida, Maryland, Minnesota, New Jersey
2024-09-17
Active, closed
ABA-101 in Participants With Progressive Multiple Sclerosis
NCT06566261Progressive Multiple Sclerosis
Abata Therapeutics
Phase 1
12
Maryland, New Jersey, Ohio
2024-09-11
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
NCT06476808High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 1
240
California, New Jersey, Ohio, Texas
2024-09-06
Active, closed
Amplitude Vascular Systems (AVS) Lithotripsy POWER PAD 2 Trial
NCT06457685Peripheral Arterial Disease (PAD)
Amplitude Vascular Systems, Inc.
Not applicable
115
Arkansas, California, Colorado, Georgia, Iowa, Missouri, New Jersey, New York
2024-09-05
Recruiting
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
NCT06393738Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Arvinas Inc.
Phase 1
329
Connecticut, Florida, Michigan, New Jersey, New York, Ohio, Tennessee, Texas
2024-09-05
Active, closed
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
BioNTech SE
Phase 2
83
California, Colorado, Connecticut, Illinois, Minnesota, New Jersey, New York, Tennessee
2024-08-26
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
93
Alabama, Arizona, California, Florida, Massachusetts, Minnesota, Missouri, New Jersey
2024-08-26
Recruiting
Abbott Structural Heart Device Registry
NCT06590467Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale
Abbott Medical Devices
Observational
2,500
California, District of Columbia, Florida, Missouri, New Jersey, New York, Ohio, Pennsylvania
2024-08-21
Recruiting
Eli Lilly and Company
Phase 1
56
Florida, Georgia, Massachusetts, New Jersey, North Carolina
2024-08-15
Recruiting
Intra-Cellular Therapies, Inc.
Phase 2
370
California, Florida, Georgia, New Jersey, North Carolina, Texas, Washington
2024-08-15
Recruiting
SuperSaturated Oxygen Comprehensive Observational Registry
NCT06438315STEMI - ST Elevation Myocardial Infarction, AMI
TherOx
Observational
1,000
California, Florida, Illinois, Kansas, Michigan, Minnesota, New Jersey, New York
2024-08-13
Active, closed
Galaxy Therapeutics INC
Phase 3
279
Illinois, New Jersey, New York
2024-08-06
Recruiting
Regeneron Pharmaceuticals
Phase 1
90
Massachusetts, New Jersey, New York, Pennsylvania, Utah
2024-08-06
Recruiting
Intra-Cellular Therapies, Inc.
Phase 2
705
California, Florida, Georgia, Michigan, New Jersey, New York, Ohio, Oklahoma
2024-08-05
Active, closed
Bristol-Myers Squibb
Observational
833
New Jersey
2024-08-02
Recruiting
Vitaccess Real MG Registry
NCT06064461Myasthenia Gravis
Vitaccess Ltd
Observational
600
California, Illinois, Kentucky, New Jersey, South Carolina, Texas
2024-07-31
Recruiting
Basking Biosciences, Inc.
Phase 2
228
Arizona, California, Florida, Michigan, Missouri, New Jersey, North Carolina, Ohio
2024-07-31
Active, closed
AbbVie
Phase 2
108
California, Kentucky, Maryland, Missouri, Nevada, New Jersey, New York, North Carolina
2024-07-29
Active, closed
OncoVerity, Inc.
Phase 2
140
Arizona, California, Colorado, Connecticut, Florida, Iowa, Kentucky, New Jersey
2024-07-22
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Arizona, California, Connecticut, Florida, Illinois, Michigan, Mississippi, New Jersey
2024-07-22
Recruiting
GlaxoSmithKline
Phase 3
150
Florida, Kansas, Missouri, New Jersey, New York, Pennsylvania, Texas
2024-07-19
Recruiting
Arbutus Biopharma Corporation
Observational
50
California, Florida, New Jersey
2024-07-11
Recruiting
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
NCT06515613Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Context Therapeutics Inc.
Phase 1
156
Arkansas, California, Colorado, Massachusetts, Nebraska, New Jersey, New York, North Carolina
2024-07-10
Active, closed
UCB Biopharma SRL
Phase 3
70
Alabama, New Jersey, North Carolina
2024-07-10
Active, closed
Safety and Efficacy of VDPHL01 in Males and Females With AGA
NCT06527365Androgenetic Alopecia, AGA, Male Pattern Baldness
Veradermics, Inc.
Phase 2
70
California, Indiana, New Jersey, Utah
2024-07-08
Active, closed
Amgen
Phase 3
89
Arizona, Illinois, Michigan, Nevada, New Jersey, Oregon, Pennsylvania, Tennessee
2024-07-05
Recruiting
Medtronic - MITG
Not applicable
278
Connecticut, Illinois, Massachusetts, New Jersey, New York
2024-06-21
Recruiting
Nipro Vascular Innovations Americas, Inc
Not applicable
159
Arizona, California, Florida, Georgia, Hawaii, Louisiana, Massachusetts, New Jersey
2024-06-20
Recruiting
Aprea Therapeutics
Phase 1
90
New Jersey, Ohio, Texas, Virginia
2024-06-13
Recruiting
Gilead Sciences
Phase 1/2
334
Alabama, Georgia, Massachusetts, New Jersey, New York, Ohio, Oklahoma, Oregon
2024-06-12
Recruiting
Home Reported Outcomes in PNH
NCT06411626Paroxysmal Nocturnal Hemoglobinuria
Novartis Pharmaceuticals
Observational
128
New Jersey
2024-06-11
Active, closed
Exelixis
Phase 2/3
600
California, Florida, Georgia, Illinois, Iowa, Missouri, New Hampshire, New Jersey
2024-06-07
Active, closed
SHINKEI Therapeutics, Inc
Phase 2
45
California, Florida, Maine, Michigan, Missouri, New Jersey, New Mexico, North Carolina
2024-06-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
California, Connecticut, Florida, Illinois, Missouri, Montana, New Jersey, New York
2024-05-24
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
220
California, Florida, Maryland, New Jersey, Ohio, Wisconsin
2024-05-20
Recruiting
Bayer
Observational
50,000
New Jersey
2024-05-15
Active, closed
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
NCT06267391Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes
Endogenex, Inc.
Not applicable
350
Alabama, California, Florida, Illinois, Iowa, Maryland, Minnesota, New Jersey
2024-05-01
By invitation
Pivotal Trial of the Boomerang Catheter for pDVA
NCT06311773Chronic Limb-Threatening Ischemia
Aveera Medical, Inc.
Not applicable
120
California, Delaware, Florida, Illinois, Louisiana, Massachusetts, New Hampshire, New Jersey
2024-04-16
Active, closed
argenx
Phase 3
119
Arizona, California, Florida, Georgia, Kansas, New Jersey, North Carolina, Ohio
2024-04-16
Active, closed
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
NCT06125951Dementia Moderate, Dementia, Mild, Alzheimer Disease
Actinogen Medical
Phase 2/3
247
California, Colorado, Florida, Georgia, New Jersey, New York, Ohio, Oregon
2024-04-12
Active, closed
Edgewise Therapeutics, Inc.
Phase 2
79
California, Georgia, Massachusetts, Michigan, Missouri, New Jersey, New York, North Carolina
2024-04-11
Recruiting
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT06276491Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor
Xencor, Inc.
Phase 1
282
California, Florida, Georgia, Illinois, Indiana, Michigan, Minnesota, New Jersey
2024-04-04
Active, closed
Exelixis
Phase 1
429
Florida, Minnesota, New Jersey, New York, Ohio, Oklahoma, Tennessee, Texas
2024-04-03
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
120
Alabama, California, Colorado, Connecticut, Kansas, Massachusetts, Missouri, New Jersey
2024-03-28
Active, closed
Anavex Life Sciences Corp.
Phase 2
71
New Jersey
2024-03-15
Active, closed
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer
Nuvation Bio Inc.
Phase 1/2
466
Michigan, New Jersey, New York, North Carolina, Texas, Utah, Virginia, Washington
2024-03-14
Recruiting
Janssen Research & Development, LLC
Phase 3
120
California, Connecticut, Georgia, Indiana, Massachusetts, New Jersey, New York, Ohio
2024-03-13
Recruiting
Eli Lilly and Company
Phase 3
90
California, Connecticut, Georgia, Indiana, Massachusetts, New Jersey, New York, Ohio
2024-03-13
Recruiting
AstraZeneca
Phase 1/2
60
California, Florida, Georgia, Kansas, Massachusetts, Missouri, New Jersey, New York
2024-03-12
Active, closed
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer
BeiGene
Phase 1
103
California, Florida, Missouri, New Jersey, South Dakota, Texas
2024-03-11
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New Jersey
2024-03-07
Recruiting
Daiichi Sankyo
Phase 2/3
860
Alaska, Connecticut, Florida, Indiana, Kentucky, Massachusetts, Missouri, New Jersey
2024-02-27
Recruiting
Sonavex, Inc.
Not applicable
304
Alabama, Arizona, Florida, Illinois, Kansas, Massachusetts, Michigan, New Jersey
2024-02-21
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Amgen
Phase 3
404
California, Connecticut, Florida, Kentucky, Louisiana, New Jersey, New York, North Carolina
2024-02-20
Active, closed
Pfizer
Phase 1
100
Florida, Georgia, Indiana, Maryland, Massachusetts, Nebraska, New Hampshire, New Jersey
2024-02-20
Active, closed
Tourmaline Bio, Inc., a Novartis Company
Phase 2
79
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Nevada, New Jersey
2024-02-19
Active, closed
Pfizer
Phase 1/2
71
Arkansas, California, Colorado, Connecticut, Michigan, New Jersey, New York, Texas
2024-02-19
Active, closed
argenx
Phase 2
103
California, Florida, Illinois, New Jersey, New York, Ohio, Texas
2024-02-17
Active, closed
Janssen Research & Development, LLC
Phase 2
305
Arizona, California, Georgia, Illinois, Missouri, Nevada, New Jersey, New York
2024-02-16
Active, closed
AstraZeneca
Phase 2
58
Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2024-02-13
Recruiting
Busulfan Sample Collection Study
NCT05711732Subjects Treated With Busulfan
Saladax Biomedical, Inc.
Observational
150
Illinois, New Jersey, Texas
2024-02-08
Active, closed
Astellas Gene Therapies
Not applicable
119
Georgia, Kansas, Michigan, Minnesota, New Jersey, Ohio, Pennsylvania, Utah
2024-02-01
Recruiting
Larimar Therapeutics, Inc.
Phase 2
85
California, Florida, Iowa, Maryland, New Jersey, Ohio, Pennsylvania, Utah
2024-01-25
Recruiting
Natera, Inc.
Observational
4,000
Arizona, California, Florida, Mississippi, New Jersey, New York, Texas
2024-01-25
Recruiting
Vividion Therapeutics, Inc.
Phase 1
280
Arizona, California, Georgia, Illinois, Kentucky, Michigan, New Jersey, North Carolina
2024-01-25
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
339
California, Connecticut, Florida, Michigan, New Jersey, New York, North Carolina, Ohio
2024-01-23
Active, closed
Boehringer Ingelheim
Phase 1
65
Florida, Georgia, Illinois, New Jersey, Pennsylvania
2024-01-22
Recruiting
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05967416Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
SIRPant Immunotherapeutics, Inc.
Phase 1
24
California, New Jersey, Texas
2024-01-17
Recruiting
Tidal Medical Technologies
Observational
500
Maryland, Minnesota, New Jersey
2024-01-16
Active, closed
Kyowa Kirin Co., Ltd.
Phase 2
185
Arizona, California, Colorado, Florida, Maryland, Nevada, New Jersey, New Mexico
2024-01-09
Recruiting
Incyte Corporation
Phase 1
710
Arizona, California, Colorado, Florida, Maryland, Massachusetts, New Jersey, New York
2024-01-04
Active, closed
TVAX Biomedical
Phase 2/3
120
Arizona, California, Florida, Georgia, Kansas, New Jersey, Oregon
2023-12-27
Recruiting
Janssen Research & Development, LLC
Phase 1
300
Arizona, California, Colorado, Florida, Georgia, Illinois, Michigan, New Jersey
2023-12-20
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
148
California, Colorado, Kentucky, Michigan, New Jersey, New York, North Carolina, Texas
2023-12-19
Active, closed
AstraZeneca
Phase 1/2
94
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, New Jersey
2023-12-14
Active, closed
Gilead Sciences
Phase 2
181
California, Florida, Maryland, New Jersey, New York, Pennsylvania, Texas, West Virginia
2023-12-13
Active, closed
AstraZeneca
Phase 2
108
New Jersey, New York, Ohio, Pennsylvania, Texas
2023-12-13
Recruiting
Georgiamune Inc
Phase 1/2
111
California, Florida, Kentucky, New Jersey, Tennessee, Texas, Virginia
2023-12-12
Active, closed
Johnson & Johnson Enterprise Innovation Inc.
Phase 1
67
Georgia, New Jersey, New York, Oregon, Pennsylvania, Virginia
2023-11-27
Recruiting
NKGen Biotech, Inc.
Phase 1/2
36
California, Florida, New Jersey, New York
2023-11-21
Active, closed
Gilead Sciences
Phase 2
253
Alabama, California, District of Columbia, Georgia, Massachusetts, New Jersey, New York, North Carolina
2023-11-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
California, Florida, Georgia, Michigan, Minnesota, Mississippi, Nebraska, New Jersey
2023-11-12
Active, closed
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
NCT05799274Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma
Radiopharm Theranostics, Ltd
Phase 1
9
New Jersey, New York
2023-11-09
Active, closed
Bristol-Myers Squibb
Phase 2
227
Alabama, Colorado, Florida, Illinois, Indiana, Missouri, New Jersey, New York
2023-11-07
Recruiting
MBrace Therapeutics
Phase 1/2
130
California, Colorado, Georgia, Illinois, Indiana, Michigan, Nevada, New Jersey
2023-11-07
Active, closed
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
NCT05784441Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 1
21
Iowa, Kentucky, Minnesota, New Jersey, Ohio, Pennsylvania, Texas
2023-11-06
Recruiting
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
NCT05901285Advanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab
Vaxiion Therapeutics
Phase 1
48
Arizona, Colorado, District of Columbia, Massachusetts, New Hampshire, New Jersey, Ohio
2023-11-02
Recruiting
Janssen Research & Development, LLC
Phase 1
355
Colorado, Georgia, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania
2023-11-01
Recruiting
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
NCT05970497Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
Krystal Biotech, Inc.
Phase 1/2
240
California, Florida, Indiana, Michigan, Nebraska, New Jersey, New York, Ohio
2023-10-31
Active, closed
Ocugen
Phase 1/2
60
Arizona, Florida, Indiana, Mississippi, Missouri, New Jersey, North Carolina, Pennsylvania
2023-10-27
Active, closed
Chengdu Origen Biotechnology Co., Ltd.
Phase 1
25
Arizona, Illinois, Massachusetts, Nevada, New Jersey, Tennessee, Texas
2023-10-16
Active, closed
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05891171Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
Arcus Biosciences, Inc.
Phase 1
40
Arizona, California, Florida, Illinois, Indiana, Michigan, Minnesota, New Jersey
2023-10-13
Active, closed
Bristol-Myers Squibb
Phase 3
106
California, Connecticut, Florida, Kansas, Kentucky, Michigan, Missouri, New Jersey
2023-10-05
Active, closed
Acrotech Biopharma Inc.
Phase 3
504
California, Colorado, Florida, Kentucky, Michigan, New Jersey, Ohio, Texas
2023-10-04
Active, closed
Expanded Indications in the Pediatric BONEBRIDGE Population
NCT05615649Hearing Loss, Conductive, Hearing Loss, Mixed
Med-El Corporation
Not applicable
36
Colorado, Florida, New Jersey, North Carolina, Ohio, Utah
2023-10-03
Active, closed
Apellis Pharmaceuticals, Inc.
Observational
300
California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota, New Jersey
2023-09-28
Recruiting
BeOne Medicines
Phase 1
337
California, Connecticut, Florida, Michigan, New Jersey, New York, Oregon, Texas
2023-09-21
By invitation
Denali Therapeutics Inc.
Phase 2/3
99
California, Illinois, New Jersey, North Carolina, Ohio, Pennsylvania, Texas, Utah
2023-09-20
Recruiting
Hoffmann-La Roche
Phase 3
230
Arizona, California, District of Columbia, Maryland, Massachusetts, Michigan, Nevada, New Jersey
2023-09-08
Active, closed
Venclose digiRF System Post Market Study
NCT05504070Venous Reflux, Chronic Venous Insufficiency
C. R. Bard
Not applicable
203
Colorado, Hawaii, Michigan, New Jersey, North Carolina, Texas, Virginia
2023-09-08
Active, closed
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
NCT05979779Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
DrugHU6
Rivus Pharmaceuticals, Inc.
Phase 2
219
California, Florida, Louisiana, New Jersey, North Dakota, Texas
2023-09-05
Rows per page Showing 1–500 of 787
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 November 2026. https://priyalifescience.com/clinical-trials-usa/state/new-jersey

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,148 studies in total at the last sync on 21 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 787 of those studies with a site in New Jersey.

How many clinical trials are recruiting in New Jersey?

426 of the 787 studies on this page are recruiting new participants as of the 21 Nov 2026, 03:16 UTC sync. A further 27 have not yet opened recruitment, 310 are active but closed to new participants, and 24 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (New Jersey), 787 studies
PhaseStudiesRecruitingShare
Phase 31517519.2%
Phase 21466818.6%
Phase 11429118%
Phase 1/21137214.4%
Observational1116414.1%
Not applicable893811.3%
Phase 2/322122.8%
Phase 41161.4%
Early Phase 1200.3%

Most active sponsors

Lead sponsors with the most studies (New Jersey)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC3321
AstraZeneca3011
Novartis Pharmaceuticals2519
Bristol-Myers Squibb2415
Pfizer2110
Janssen Research & Development, LLC176
Hoffmann-La Roche157
AbbVie148
Regeneron Pharmaceuticals137
Gilead Sciences127
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.